the aid library

LIST OPTIONS

Filter

4174

Global programme to eliminate lymphatic filariasis: progress report, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co... more

Download (730)

View PDF (1522)

Guidelines on hepatitis B and C testing
recommended

World Health Organization (WHO) (2017) C_WHO

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to recei... more

Download (160)

View PDF (205)

Prevention and Control of Non-Communicable Diseases in Zambia: The Case for Investment

Ministry of Health, Zambia (2020) CC

The Government of the Republic of Zambia has placed priority on ensuring that Zambians are healthy and productive as a catalyst to the attainment of socioeconomic development . The Vision 2030 aims to transform Zambia into a prosperous middle-income country as articulated also in the 7th National De... more

External Link

Impact of human schistosomiasis in sub-Saharan Africa

Adenowo, A.; Oyinloye, B.; Ogunyinka, B. et al. (2015) CC

Human schistosomiasis otherwise called bilharzia, is a fresh- water snail transmitted intravascular debilitating disease resulting from infection by the parasitic dimorphic Schistosoma trematode worms, which lives in the bloodstream of humans. The World Health Organization (WHO) regards the disease ... more

Download (96)

View PDF (100)

Acute schistosomiasis, a diagnostic and therapeutic challenge

Jauréguiberry S., Paris L., Caumes E. (2010) C2

Clin Microbiol Infect 2010; 16: 225–231 Abstract In non-endemic countries, acute (invasive) schistosomiasis (AS) is typically seen in non-immune travellers, whereas chronic schistosomiasis is more frequently diagnosed in immigrants. Travellers with AS initially present with non-specific signs such... more

External Link

Noncommunicable Diseases

PAHO - Pan American Health Organization (2023) CC

The term NCDs refers to a group of conditions that are not mainly caused by an acute infection, result in long-term health consequences and often create a need for long-term treatment and care. These conditions include cancers, cardiovascular disease, diabetes and chronic lung illnesses.

External Link

Sangath

(2019) CC

Sangath is a non-governmental, not-for-profit organisation committed to improving health across the life span by empowering existing community resources to provide appropriate physical, psychological and social therapies. Its primary focus areas include child development, adolescent and youth health... more

Download (287)

View PDF (367)

The Socio-Economic Impact of People Living with HIV at the Household Level in Myanmar

Cercone, James; Pinder, Étoile; Pothuis, Michal et al. The Republic of the Union of Myanmar, Ministry of Health and Sports; UNDP (2016) C1

The study collected data on the impact of HIV-related diseases on income, revenues, economic dependency, consumption, education, health, food security, stigma, discrimination, quality of life, and migration. The study also assessed people living with chronic diseases in order to compare the impact o... more

Download (434)

View PDF (558)

WHO Nutrient Profile Model for South-East Asia Region

World Health Organization (WHO), Regional Office for South-East Asia (2017) C_WHO

To implement the set of recommendations on the marketing of foods and non-alcoholic beverages to children
With the growing obesity crisis among children, WHO and other public health advocates and consumer groups have called for restrictions on advertising of ‘unhealthy foods’ high in salt, ... more

Download (129)

View PDF (158)

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015(2016 interim update)

British HIV Association (2016) CC

The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ... more

Download (167)

View PDF (209)

Christian Responses to Health and Development

German Institute for Medical Mission (2014) C2

In 1964 medical mission was challenged and called to define its distinctiveness and its special role in the context of that particular time. The consultation "Tuebingen I" clearly stated: "The Christian church has a specific task in the field of health and healing"1, and developed a conce... more

Download (140)

View PDF (183)

International standards for the treatment of drug use disorders - Revised Edition Incorporating Results Of Field - Testing

World Health Organization WHO (2020) C_WHO

This document is based on currently available scientific evidence on treatment for drug use disorders and sets out a framework for the implementation of the Standards, in line with principles of public health care. The Standards identify major components and features of effective systems for the tre... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (505)

View PDF (907)

State of Health in the WHO African Region
recommended

World Health Organization WHO, Regional Office African Region (2018) C_WHO

This report is not a country scorecard. Rather, its purpose is to act as a compass to guide progress towards health in the SDGs. There has been a significant improvement in the state of health in the region with healthy life expectancy - time spent in full health - in the region increasing from 50... more

Download (209)

View PDF (138)

Implementation Framework & Clinical Guidance for Viral Hepatitis Prevention & Treatment 2019

Ministry of Health, Zambia (2020) CC

The Zambia Population Based HIV impact assessment of 2016, reported the prevalence of viral hepatitis in Zambia as ranging between 5.6% among adults aged 15 to 59% in the general population, and 7.1% among HIV infected individuals. It is estimated that the majority of persons with chronic hepatitis ... more

External Link

Air Pollution - WHO

World Health Organisation (WHO) (2022) C_WHO

Accessed on 06.03.2022 Air pollution is contamination of the indoor or outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere. Household combustion devices, motor vehicles, industrial facilities and forest fires are common sou... more

External Link

Ukraine: People with chronic diseases face massive challenges in accessing health care

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

22 April 2022

Guidelines on hepatitis B and C testing recommended

State of Health in the WHO African Region recommended

Guidelines on hepatitis B and C testing
recommended

State of Health in the WHO African Region
recommended